Clinical Trials Browser

Phase 1/2 × BMS-833923 × Other hematologic neoplasm × Clear all

NCT01218477 2016-06-17

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Phase 1/2 Completed

33 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase